A Fellowship For U.S.-Japanese Harmony

Recent events have resulted in a great deal of publicity about competitiveness. Among the so-called races in high technology, the biotechnology race has attracted much attention and comment. In the United States, there is much concern about the perceived possibility that history may repeat itself, and that a technology that was invented in the United States may find its most impressive commercial applications developed in Japan. It is all very well to talk about competitiveness, not withstandi

Written byRonald Cape
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

It is all very well to talk about competitiveness, not withstanding much of the belligerent nonsense we have recently heard and read. Every academic and industrial unit should aspire to be as competitive as possible. The best ones accomplish this, and their productivity attests to that. But to focus only on competition, as seems to be the vogue today, risks missing some very important aspects of biotech nology in 1987, and for the rest of this century.

The field continues to grow dynamically, almost explosively. The scientific breakthroughs don't seem to relevant, and given challenges such as that presented by AIDS, all humankind must be very thankful for that! Many of these advances promise markets and changes that we can hardly contemplate. Most important, no one has a monopoly on what is necessary to succeed in this field, so we see dramatic developments in many corners of the world.

No ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies